Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

958
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
958
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

399
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
399
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

363
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
363

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025.

Heart views : the official journal of the Gulf Heart Association·2026
Same author

Consistency of HFrEF treatment effect in underrepresented groups in randomized clinical trials.

NPJ cardiovascular health·2026
Same author

Closing the Gap, A Commentary on Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute Heart Failure: The REHAB-HF Trial.

JACC. Heart failure·2025
Same author

Rationale and design of the comparative effectiveness of ICD vs non-ICD therapy in contemporary heart failure patients at a low risk for arrhythmic death (CONTEMP-ICD) trial.

American heart journal·2025
Same author

Social Drivers of Health in Heart Failure Trials: An Analysis From the Heart Failure Collaboratory.

JACC. Heart failure·2025
Same author

iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025.

Heart, lung & circulation·2025

Related Experiment Video

Updated: Feb 13, 2026

Sex Differences in Mouse Hippocampal Astrocytes after In-Vitro Ischemia
08:32

Sex Differences in Mouse Hippocampal Astrocytes after In-Vitro Ischemia

Published on: October 25, 2016

13.9K

Sex differences in heart failure.

Evann Eisenberg1, Katherine E Di Palo2, Ileana L Piña3

  • 1Department of Cardiology, Cedars-Sinai Medical Center, California, Los Angeles.

Clinical Cardiology
|February 28, 2018
PubMed
Summary
This summary is machine-generated.

Heart failure (HF) affects many women, yet gender differences in its recognition, diagnosis, and treatment are often overlooked. Understanding these variations is crucial for improving care for women with heart failure.

Keywords:
Gender DifferencesHeart FailureWomen

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
In Vitro Method to Study Sex-Based Differences in Conjunctival Goblet Cells
06:28

In Vitro Method to Study Sex-Based Differences in Conjunctival Goblet Cells

Published on: July 28, 2023

863

Related Experiment Videos

Last Updated: Feb 13, 2026

Sex Differences in Mouse Hippocampal Astrocytes after In-Vitro Ischemia
08:32

Sex Differences in Mouse Hippocampal Astrocytes after In-Vitro Ischemia

Published on: October 25, 2016

13.9K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
In Vitro Method to Study Sex-Based Differences in Conjunctival Goblet Cells
06:28

In Vitro Method to Study Sex-Based Differences in Conjunctival Goblet Cells

Published on: July 28, 2023

863

Area of Science:

  • Cardiology
  • Women's Health
  • Clinical Research

Background:

  • Heart failure (HF) prevalence is increasing in the United States.
  • Approximately 50% of individuals living with HF are women.
  • Gender-specific considerations are vital for effective HF management.

Purpose of the Study:

  • To review the prevalence of heart failure in women.
  • To discuss gender-based variations in HF epidemiology, symptoms, pharmacology, and treatment.
  • To examine the representation of women in clinical trials.

Main Methods:

  • Literature review of existing studies on heart failure in women.
  • Analysis of epidemiological data, clinical presentations, and treatment responses.
  • Assessment of women's inclusion in cardiovascular clinical trials.

Main Results:

  • Heart failure affects a substantial proportion of women, with distinct epidemiological patterns.
  • Gender influences symptom recognition, diagnostic approaches, and pharmacological responses in HF.
  • Women remain underrepresented in pivotal HF clinical trials, potentially impacting evidence-based guidelines.

Conclusions:

  • Recognizing and addressing gender differences in heart failure is essential for equitable and effective patient care.
  • Further research is needed to elucidate sex-specific mechanisms and optimize treatments for women.
  • Improving the inclusion of women in clinical trials is critical for advancing HF management for all patients.